EP1189624A4 - HLA-BINDING PEPTIDES AND USES THEREOF - Google Patents

HLA-BINDING PEPTIDES AND USES THEREOF

Info

Publication number
EP1189624A4
EP1189624A4 EP00944976A EP00944976A EP1189624A4 EP 1189624 A4 EP1189624 A4 EP 1189624A4 EP 00944976 A EP00944976 A EP 00944976A EP 00944976 A EP00944976 A EP 00944976A EP 1189624 A4 EP1189624 A4 EP 1189624A4
Authority
EP
European Patent Office
Prior art keywords
binding peptides
peptides
hla binding
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00944976A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1189624A1 (en
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP07117445A priority Critical patent/EP1917970B1/en
Publication of EP1189624A1 publication Critical patent/EP1189624A1/en
Publication of EP1189624A4 publication Critical patent/EP1189624A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00944976A 1999-06-29 2000-06-28 HLA-BINDING PEPTIDES AND USES THEREOF Withdrawn EP1189624A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07117445A EP1917970B1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14142299P 1999-06-29 1999-06-29
US141422P 1999-06-29
PCT/US2000/017842 WO2001000225A1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07117445A Division EP1917970B1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Publications (2)

Publication Number Publication Date
EP1189624A1 EP1189624A1 (en) 2002-03-27
EP1189624A4 true EP1189624A4 (en) 2005-02-23

Family

ID=22495620

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00944976A Withdrawn EP1189624A4 (en) 1999-06-29 2000-06-28 HLA-BINDING PEPTIDES AND USES THEREOF
EP07117445A Expired - Lifetime EP1917970B1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07117445A Expired - Lifetime EP1917970B1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Country Status (6)

Country Link
EP (2) EP1189624A4 (enExample)
JP (1) JP2003535024A (enExample)
AT (1) ATE512666T1 (enExample)
AU (1) AU5898400A (enExample)
CA (1) CA2370413A1 (enExample)
WO (1) WO2001000225A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20040096445A1 (en) * 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CA2407104A1 (en) * 2000-05-12 2001-11-22 Northwest Biotherapeutics, Inc. Method to increase class i presentation of exogenous antigens by human dendritic cells
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2464239C (en) 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
PL1620456T3 (pl) * 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2007277092A (ja) * 2004-06-17 2007-10-25 Univ Kurume 前立腺関連抗原由来ｈｌａ−ａ２結合性ペプチド
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA3197245A1 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
CN110022893B (zh) * 2016-10-07 2023-12-29 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018126060A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN111093691A (zh) 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
NL2019814B1 (en) * 2017-10-26 2019-05-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for producing a MHC multimer.
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
US12246067B2 (en) 2018-06-19 2025-03-11 Biontech Us Inc. Neoantigens and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012238A4 (en) * 1997-01-31 2003-03-05 Epimmune Inc PEPTIDES AND ANTIQUE PRESENTING CELLS LOADED WITH PEPTIDES FOR THE ACTIVATION OF CYTOTOXIC T CELLS
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 685 - 693, XP002055570, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1917970B1 (en) 2011-06-15
AU5898400A (en) 2001-01-31
EP1917970A3 (en) 2008-09-24
ATE512666T1 (de) 2011-07-15
EP1189624A1 (en) 2002-03-27
WO2001000225A1 (en) 2001-01-04
EP1917970A2 (en) 2008-05-07
CA2370413A1 (en) 2001-01-04
JP2003535024A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
EP1189624A4 (en) HLA-BINDING PEPTIDES AND USES THEREOF
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
SG49008A1 (en) Hla-a2.1 binding peptides and their uses
EP0907370A4 (en) HLA-A2.1 BINDING PEPTIDES AND USES THEREOF
SG52492A1 (en) Hla binding peptides and their uses
GB9624456D0 (en) Assay method
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
AU5963500A (en) Peptides for vaccinating against human cmv
EP1089757A4 (en) HLA-BINDING PEPTIDES AND THEIR USE.
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
AU4791901A (en) Compositions and methods for dendritic cell-based immunotherapy
EP1320377A4 (en) HLA-BINDING PEPTIDES AND USES THEREOF
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
WO2001023560A3 (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071220